Jeon D - Search Results

1

Impact of revised definitions for extensively drug-resistant TB on disease classification.

Shin JE, Jo KW, O YJ, Jeon D, Kang H, Yim JJ, Kwon YS, Shim TS. Shin JE, et al. Among authors: jeon d. Int J Tuberc Lung Dis. 2021 Sep 1;25(9):766-768. doi: 10.5588/ijtld.21.0229. Int J Tuberc Lung Dis. 2021. PMID: 34802501 No abstract available.

2

Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation.

Jeon D, Kang H, Kwon YS, Yim JJ, Shim TS. Jeon D, et al. J Korean Med Sci. 2020 Sep 7;35(35):e284. doi: 10.3346/jkms.2020.35.e284. J Korean Med Sci. 2020. PMID: 32893517 Free PMC article.

3

Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease.

Chung C, Shin JE, Jeon D, Kang H, Yim JJ, Jo KW, Shim TS. Chung C, et al. Among authors: jeon d. Eur Respir J. 2022 Aug 10;60(2):2200930. doi: 10.1183/13993003.00930-2022. Print 2022 Aug. Eur Respir J. 2022. PMID: 35710263 Free article. No abstract available.

4

Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis.

Jeon DS, Kim DH, Kang HS, Hwang SH, Min JH, Kim JH, Sung NM, Carroll MW, Park SK. Jeon DS, et al. Int J Tuberc Lung Dis. 2009 May;13(5):594-600. Int J Tuberc Lung Dis. 2009. PMID: 19383192

5

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid.

Lee HH, Jo KW, Yim JJ, Jeon D, Kang H, Shim TS. Lee HH, et al. Among authors: jeon d. Int J Infect Dis. 2020 Sep;98:478-485. doi: 10.1016/j.ijid.2020.07.001. Epub 2020 Jul 5. Int J Infect Dis. 2020. PMID: 32640367 Free article.

6

Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.

Kwon YS, Jeon D, Kang H, Yim JJ, Shim TS. Kwon YS, et al. Among authors: jeon d. Eur Respir J. 2021 Mar 4;57(3):2003026. doi: 10.1183/13993003.03026-2020. Print 2021 Mar. Eur Respir J. 2021. PMID: 33093123 Free article. No abstract available.

7

Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.

Hwang H, Kang H, Kwon YS, Jeon D, Shim TS, Yim JJ. Hwang H, et al. Among authors: jeon d. Clin Infect Dis. 2021 Oct 20;73(8):1362-1369. doi: 10.1093/cid/ciab304. Clin Infect Dis. 2021. PMID: 33837767

8

Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort.

Carroll MW, Lee M, Cai Y, Hallahan CW, Shaw PA, Min JH, Goldfeder LC, Alekseyev V, Grinkrug S, Kang HS, Hwang S, Park HM, Kang E, Lee SY, Jin B, Park HE, Min S, Park SK, Jeon DS, Via LE, Barry CE 3rd. Carroll MW, et al. Among authors: jeon ds. Int J Tuberc Lung Dis. 2012 Jul;16(7):961-6. doi: 10.5588/ijtld.11.0574. Epub 2012 May 8. Int J Tuberc Lung Dis. 2012. PMID: 22584241 Free PMC article.

9

Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea.

Kang H, Jo KW, Jeon D, Yim JJ, Shim TS. Kang H, et al. Among authors: jeon d. Respir Med. 2020 Jun;167:105956. doi: 10.1016/j.rmed.2020.105956. Epub 2020 Apr 8. Respir Med. 2020. PMID: 32421540 Free article.

10

Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.

Mok J, Kang H, Hwang SH, Park JS, Kang B, Lee T, Koh WJ, Yim JJ, Jeon D. Mok J, et al. Among authors: jeon d. J Antimicrob Chemother. 2018 Feb 1;73(2):503-508. doi: 10.1093/jac/dkx373. J Antimicrob Chemother. 2018. PMID: 29069496

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,053 results

Search Page

Filters